Novartis’ Kisqali (Ribociclib) Secures EC’s Approval as an Adjuvant Treatment of HR+/HER2- Early Breast Cancer
Shots:
- The EC has granted approval to Kisqali in addition to aromatase inhibitor (AI) as an adjuvant treatment of HR+/HER2- early breast cancer (EBC) patients at high risk of recurrence, with global reviews underway
- The approval was supported by P-III (NATALEE) study (conducted in partnership with TRIO) assessing Kisqali + ET vs ET alone as an adj. treatment of patients (n=5,101) with stage II & III HR+/HER2- EBC, incl. those with node-negative disease
- Trial depicted a significantly reduced risk of disease recurrence by 25.1%, with a consistent iDFS benefits across all patient population. Trial continues to assess longer-term results such as OS
Ref: Novartis | Image: Novartis
Related News:- Novartis Reports the US FDA’s Approval of Kisqali (Ribociclib) for the Treatment of HR+/HER2- Early Breast Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
